BPTH vs. ATHA, NKGN, GLYC, AFMD, SPRB, HCWB, SYBX, NRSN, EGRX, and MTVA
Should you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Athira Pharma (ATHA), NKGen Biotech (NKGN), GlycoMimetics (GLYC), Affimed (AFMD), Spruce Biosciences (SPRB), HCW Biologics (HCWB), Synlogic (SYBX), NeuroSense Therapeutics (NRSN), Eagle Pharmaceuticals (EGRX), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry.
Bio-Path vs.
Bio-Path (NASDAQ:BPTH) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
In the previous week, Bio-Path and Bio-Path both had 1 articles in the media. Bio-Path's average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.
Bio-Path has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500.
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Bio-Path currently has a consensus target price of $20.00, indicating a potential upside of 10,710.81%. Athira Pharma has a consensus target price of $13.83, indicating a potential upside of 3,043.94%. Given Bio-Path's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Path is more favorable than Athira Pharma.
Bio-Path received 262 more outperform votes than Athira Pharma when rated by MarketBeat users. However, 54.05% of users gave Athira Pharma an outperform vote while only 53.51% of users gave Bio-Path an outperform vote.
Athira Pharma's return on equity of -115.62% beat Bio-Path's return on equity.
Summary
Athira Pharma beats Bio-Path on 6 of the 11 factors compared between the two stocks.
Get Bio-Path News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Path Competitors List
Related Companies and Tools
This page (NASDAQ:BPTH) was last updated on 2/21/2025 by MarketBeat.com Staff
